Bristol-Myers Squibb (BMY) stock slips despite earnings beat

Go back to Bristol-Myers Squibb (BMY) stock slips despite earnings beat

Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank

April 29, 2024 5:27 AM EDT

Deutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.

The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More

Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue

April 25, 2024 7:00 AM EDT

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of ($4.40), $0.07 better than the analyst estimate of ($4.47). Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.46 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

... More